<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910674</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0004</org_study_id>
    <nct_id>NCT02910674</nct_id>
  </id_info>
  <brief_title>Dario Blood Glucose Monitoring System - Android Devices User Performance Study Report</brief_title>
  <official_title>Dario Blood Glucose Monitoring System - Android Devices User Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LabStyle Innovations Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LabStyle Innovations Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the accuracy of the Dario Blood Glucose Monitoring&#xD;
      System as compared to a reference method (Yellow Springs Instrument 2300 STAT Plus) and to&#xD;
      evaluate the usability of the device when used by laypersons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives for this study are to evaluate the blood glucose level results obtained from&#xD;
      the subject's fingertip using the Dario Blood Glucose Monitoring System paired with a&#xD;
      reference device from one of three Android smart mobile device families as compared to the&#xD;
      results from the Yellow Springs Instrument 2300 STAT Plus. The usability of the Dario Blood&#xD;
      Glucose Monitoring System when paired with a reference device from one of three Android smart&#xD;
      mobile device families and used by laypersons is also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of Glucose Concentrations (%)</measure>
    <time_frame>1 Day</time_frame>
    <description>Accuracy acceptability is defined as follows:&#xD;
Ninety-five percent (95%) of the individual glucose results shall fall within +/-15 mg/dL of the results of the Dario's measurement at glucose concentrations &lt; 75 mg/dL and within +/- 20% at glucose concentrations greater than or equal to 75 mg/dL.&#xD;
The accuracy of the Dario Blood Glucose Monitoring System when used with Android operating system smart mobile devices was assessed against the Yellow Springs Instrument 2300 STAT Plus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Rank of the Indication of &quot;How Would Rate Your Success in Operating Dario BGMS&quot;</measure>
    <time_frame>1 Day</time_frame>
    <description>Using a scale of 1-5 where 1-completely fails, 2-unsuccessful, 3-Partially successful, 4-successful, 5-very successful.&#xD;
Average rank of 3.5 ('average'/'successful') or above in question #2 - How would you rate your success in operating Dario™ BGMS?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Rank of the Indication of &quot;How Easy Was it to Operate the Dario™ BGMS on the First Time?&quot;</measure>
    <time_frame>1 Day</time_frame>
    <description>Using a scale of 1-5 where 1-very hard, 2-hard, 3-average, 4-easy, 5-very easy.&#xD;
An average rank of 3 ('average') or above in question #3 - How easy was it to operate the Dario™ BGMS on the first time?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Responding 'YES' on the Question &quot;Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?&quot;</measure>
    <time_frame>1 Day</time_frame>
    <description>The acceptance criteria for this question is: at least ninety percent (90%) need to answer 'Yes' on question #1 - Did you successfully obtain measurement result using the Dario™ BGMS?&#xD;
100% of subjects (102 of 102) answered &quot;Yes&quot; to this question.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>One Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a comparative diagnostic study, no interventional actions are being taken.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dario Blood Glucose Monitoring System</intervention_name>
    <description>Accuracy with usability assessment</description>
    <arm_group_label>One Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has Type 1 or Type II diabetes&#xD;
&#xD;
          -  Subject speaks and reads English proficiently&#xD;
&#xD;
          -  Subject is able and agrees to sign the informed consent form (minor subjects must be&#xD;
             accompanied by a parent or legal guardian to provide consent for their participation&#xD;
             in the study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has medical training or works in the field of blood glucose monitoring&#xD;
             systems.&#xD;
&#xD;
          -  Subject is critically ill.&#xD;
&#xD;
          -  Subject has an impairment that prevents him/her from following the study procedures.&#xD;
&#xD;
          -  Subject has any condition that the Principal Investigator believes may interfere in&#xD;
             the subject's participation in the study.&#xD;
&#xD;
          -  Hematocrit levels outside the range of 20%-60%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>April 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diabetes (Type I or II), Ages 13-80</title>
          <description>Males and females with diabetes (type I or II), ages 13-80 recruited through advertisement, outpatient clinics, physician offices, and similar sources.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetes (Type I or II), Ages 13-80</title>
          <description>Males and females with diabetes (type I or II), ages 13-80 recruited through advertisement, outpatient clinics, physician offices, and similar sources.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subjects with Type I and Type II diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Accuracy of Glucose Concentrations (%)</title>
        <description>Accuracy acceptability is defined as follows:&#xD;
Ninety-five percent (95%) of the individual glucose results shall fall within +/-15 mg/dL of the results of the Dario's measurement at glucose concentrations &lt; 75 mg/dL and within +/- 20% at glucose concentrations greater than or equal to 75 mg/dL.&#xD;
The accuracy of the Dario Blood Glucose Monitoring System when used with Android operating system smart mobile devices was assessed against the Yellow Springs Instrument 2300 STAT Plus.</description>
        <time_frame>1 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetes (Type I or II), Ages 13-80</title>
            <description>Males and females with diabetes (type I or II), ages 13-80 recruited through advertisement, outpatient clinics, physician offices, and similar sources.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of Glucose Concentrations (%)</title>
          <description>Accuracy acceptability is defined as follows:&#xD;
Ninety-five percent (95%) of the individual glucose results shall fall within +/-15 mg/dL of the results of the Dario's measurement at glucose concentrations &lt; 75 mg/dL and within +/- 20% at glucose concentrations greater than or equal to 75 mg/dL.&#xD;
The accuracy of the Dario Blood Glucose Monitoring System when used with Android operating system smart mobile devices was assessed against the Yellow Springs Instrument 2300 STAT Plus.</description>
          <units>percentage of measurements within range</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Rank of the Indication of &quot;How Would Rate Your Success in Operating Dario BGMS&quot;</title>
        <description>Using a scale of 1-5 where 1-completely fails, 2-unsuccessful, 3-Partially successful, 4-successful, 5-very successful.&#xD;
Average rank of 3.5 ('average'/'successful') or above in question #2 - How would you rate your success in operating Dario™ BGMS?</description>
        <time_frame>1 Day</time_frame>
        <population>102 ranked their success in operating Dario™ BGMS 1-5. 1- Completely failed, 5- Very successful</population>
        <group_list>
          <group group_id="O1">
            <title>One Arm</title>
            <description>This is a comparative diagnostic study, no interventional actions are being taken.&#xD;
Dario Blood Glucose Monitoring System: Accuracy with usability assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rank of the Indication of &quot;How Would Rate Your Success in Operating Dario BGMS&quot;</title>
          <description>Using a scale of 1-5 where 1-completely fails, 2-unsuccessful, 3-Partially successful, 4-successful, 5-very successful.&#xD;
Average rank of 3.5 ('average'/'successful') or above in question #2 - How would you rate your success in operating Dario™ BGMS?</description>
          <population>102 ranked their success in operating Dario™ BGMS 1-5. 1- Completely failed, 5- Very successful</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Rank of the Indication of &quot;How Easy Was it to Operate the Dario™ BGMS on the First Time?&quot;</title>
        <description>Using a scale of 1-5 where 1-very hard, 2-hard, 3-average, 4-easy, 5-very easy.&#xD;
An average rank of 3 ('average') or above in question #3 - How easy was it to operate the Dario™ BGMS on the first time?</description>
        <time_frame>1 Day</time_frame>
        <population>102 ranked their ease in operating Dario™ BGMS 1-5. 1- Very Hard, 5- Very Easy</population>
        <group_list>
          <group group_id="O1">
            <title>One Arm</title>
            <description>This is a comparative diagnostic study, no interventional actions are being taken.&#xD;
Dario Blood Glucose Monitoring System: Accuracy with usability assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rank of the Indication of &quot;How Easy Was it to Operate the Dario™ BGMS on the First Time?&quot;</title>
          <description>Using a scale of 1-5 where 1-very hard, 2-hard, 3-average, 4-easy, 5-very easy.&#xD;
An average rank of 3 ('average') or above in question #3 - How easy was it to operate the Dario™ BGMS on the first time?</description>
          <population>102 ranked their ease in operating Dario™ BGMS 1-5. 1- Very Hard, 5- Very Easy</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Responding 'YES' on the Question &quot;Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?&quot;</title>
        <description>The acceptance criteria for this question is: at least ninety percent (90%) need to answer 'Yes' on question #1 - Did you successfully obtain measurement result using the Dario™ BGMS?&#xD;
100% of subjects (102 of 102) answered &quot;Yes&quot; to this question.</description>
        <time_frame>1 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>One Arm</title>
            <description>This is a comparative diagnostic study, no interventional actions are being taken.&#xD;
Dario Blood Glucose Monitoring System: Accuracy with usability assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Responding 'YES' on the Question &quot;Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?&quot;</title>
          <description>The acceptance criteria for this question is: at least ninety percent (90%) need to answer 'Yes' on question #1 - Did you successfully obtain measurement result using the Dario™ BGMS?&#xD;
100% of subjects (102 of 102) answered &quot;Yes&quot; to this question.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Days</time_frame>
      <desc>Reporting requirements are provided in compliance with 21 CFR 812.150(b) (1). All-Cause Mortality: No mortalities were recorded during the study Serious Adverse Events: No serious adverse events were recorded during the study Other (Not Including Serious) Adverse Events: No other adverse events were recorded during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Diabetes (Type I or II), Ages 13-80</title>
          <description>Males and females with diabetes (type I or II), ages 13-80 recruited through advertisement, outpatient clinics, physician offices, and similar sources.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Satish K. Garg</name_or_title>
      <organization>Barbara Davis Center for Childhood Diabetes</organization>
      <phone>303.724.6713</phone>
      <email>satish.garg@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

